RU
Address
220006, Minsk, Leningradskaya Str. 6, office 2
Tel.: +375 17 363-88-92
E-mail: medjournal@bsmu.by

Современные подходы к диагностике и лечению cинегнойной инфекции у больных муковисцидозом

И.В. Бобровничий УО «Белорусский государственный медицинский университет»
2012 №1 | Клинический обзор
Аннотация
Список литературы
Скачать полнотекстовую статью
В данной статье представлен обзор современных данных о Ps. aeruginosa и ее роль при муковисцидозе. Приводятся методы диагностики и антибактериальной терапии Ps. aeruginosa у больных муковисцидозом.
Ключевые слова:
Ps. aeruginosa, муковисцидоз, дети, диагностика, антибиотики, лечение
Modern approaches to diagnosis and treatment of pseudomonas aeruginosa infection in a patient with cystic fibrosis

This article provides an overview of recent data on Ps. aeruginosa and its role in cystic fibrosis. The methods of diagnostic and antibiotic therapy Ps. aeruginosa in cystic fibrosis patients.

Keywords
pseudomonas aeruginosa, cystic fibrosis, children, diagnostic, antibiotics, treatment
  • 1. Бобровничий, В. И. Антибактериальная терапия у больных муковисцидозом: методические рекомендации / В. И. Бобровничий. – Минск: БГМУ, 2003. – 38 с.
  • 2. Борисов, Л. Б. Медицинская микробиология, вирусология, иммунология /Л. Б. Борисов. М.: ООО «Мед. информ. агенство»; 2001. С. 418 – 421.
  • 3. Капранов, Н. И. Клиническое значение современных макролидов в рациональной антибиотикотерапии хронической бронхолегочной инфекции Ps. aeruginosa у больных муковисцидозом/Н. И. Капранов, А. Л. Пухалъский, А. М. Радионовин, Н. Ю. Каширская// Педиатрия. 2003. Т. 5. С. 19 – 27.
  • 4. Клинический протокол диагностики, лечения и реабилитации больных кистозным фиброзом (муковисцидозом). Приказ МЗ РБ № 142 от 25 февраля 2008 года.
  • 5. Консенсус конференция Европейского общества помощи больным муковисцидозом (ECFC). Муковисцидоз. 2004; 4: 2.
  • 6. Певницкий, Л. А. Иммунологический мониторинг больных муковисцидозом. Значение различных лабораторных показателей/ Л. А. Певницкий, А. Л. Пухальский, Н. И. Капранов и др.// Вестн. РАМН. 2000. Т. 5. С. 40 – 46.
  • 7. Anonymous. Cystic fibrosis foundation patient registry 1997 annual data report. Bethesda, MD, USA. Cystic Fibrosis Foundation 1998.
  • 8. Berger, M. Complement receptor expression on neutrophils at the inflammatory site, The Pseudomonasinfected lung in cystic fibrosis/ М. Berge, R. U. Sorensen, M. F. Tosi et al //J. Clin. Invest. 1989. V.84. Р. 1302 – 1313.
  • 9. Bonfield, T. L. Inflammatory cytokines in cystic fibrosis lungs/ T. L. Bonfield, J. R. Panuska, M. W. Konstan et al // Am J. Respir. Crit. Care Med. 1995. V. 152. № 8. Р. 2111.
  • 10. Botzenhart, K. Epidemiology and ecology of Pseudomonas aeruginosa/ K. Botzenhart, G. Doring// In: Campa M, Bendinelli M, Friedman H, eds. Pseudomonas aeruginosa as an opportunistic pathogen. New York, Plenum Press. 1993. Р. 1 – 18.
  • 11. Burns, J. L. Microbiology of sputum from patients at cystic fibrosis centers in the United States/ J. L. Burns, J. Emerson, J. R. Stapp et al // Clin. Infect. Dis. 1998. V. 27. Р. 158 – 163.
  • 12. Burns, J. L. Longitudinal assessment of in Pseudomonas aeruginosa young children with cystic fibrosis/ J. L. Burns, R. L. Gibson, S. McNamara et al// J. Infect. Dis. 2001. 183:444 – 452.
  • 13. Cigana, C. Azithromycin inhibits Nuclear Factor (NF¬kB) activity and expression of interleukin 8 in CF airway epithelial cells/ C. Cigana, E. Nicolis., M. Pasetto. еt al // J. Cyst. Fibros. 2005. 4: S31, abstr. 114.
  • 14. Crevvata, M. I. Biofilm formation and antimicrobial resistance of clinical CNS isolates are associated with slimspecific 20¬kDa PS antigen/ M. I. Crevvata, F. Kolonitsiou, P. Kotsantis et al.// In: 11 th International Cogress on Infections Diseases. Cancun, Mexico. 2004. Abstr. № 56.002. On dick.
  • 15. Cystic Fibrosis Foundation Patient Registry 2001 Annual Data Report. Bethesda, MD, USA. Cystic Fibrosis Foundation. 2002.
  • 16. Dakin, C. J. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis/ C. J. Dakin, A. H. Numa, H. Wang еt al// Amer. J. Respir. Crit. Care Med. 2002. V. 165. Р. 904 – 910.
  • 17. De Boeck, К. Sputum induction in young cystic fibrosis patients / К. De Boeck, М. Alifier, S. Vandeputte// Eur. Respir. J. 2000. V. 16. Р. 91 – 94.
  • 18. De Rose, V. Mechanisms and markers of airway inflammation in cystic fibrosis / V. De Rose// Eur. Respir. J. 2002. V. 19. Р. 333 – 340.
  • 19. Delden, C. Celltocell signaling and Pseudomonas aeruginosa infections/ C. Delden, B. Iglewski //Emerg. Infect. Dis. 1998. V. 4 (4). Р. 551 – 560.
  • 20. Doring, G. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus/ G. Doring, S. P. Conway, H. G. M. Heijerman еt al // Eur. Respir. J. 2000. V.16. Р. 749 – 767.
  • 21. Doring, G. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis/ G. Doring, N. Hoiby// Infect. Immun. 1983. V. 42. Р. 197 – 201.
  • 22. Doring, G. Immunology of cystic fibrosis. In: Morlin ME, Hedges GL, Smith AL, Burns JL, eds. Cystic Fibrosis. Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa/ G. Doring, R. Knight, G. Bellon //J. Clin. Microbiol. 1994. V. 32. Р. 1027 – 1030.
  • 23. Doring, G. Early intervention and prevention of lung disease in cyst\ic fibrosis. In: 2 nd Draft manuscript prepared for the Consensus Study Group after the consensus meeting in Artimino/ G. Doring, N. Hoiby //J. Cyst. Fibros. 2004. V.3 (2). Р. 67 – 91.
  • 24. Filloux, A. Biofilm: setup and organization of a bacterial community. A. Filloux, I. Vallet// Med.Sci. 2003. V. 19. Р. 77 – 83.
  • 25. Gay. lor A. Therapy with macrolides in patients with cystic fibrosis / A. Gay lor, C. Reilly// Pharmacotherapy. 2002. V. 22 (2). Р. 227 – 239.
  • 26. Gibson, R. L. Pathophysiology & management of pulmonary infections in CF / R. L. Gibson, J. Burns, B. Ramsey //Am. J. Respir. Crit. Care Med. 2003. V. 168. Р. 918 – 951.
  • 27. Gilligan, P. H. Pseudomonas and Burkholderia. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology/ P. H. Gilligan // 6 th ed. Washington, DC, ASM Press. 1995. Р. 509 – 519.
  • 28. Govan, J. R. W. Microbiology of cystic fibrosis lung infections: themes and issues/ J. R. W. Govan J. Nelson //J. R. Soc. Med. 1993. V. 86(suppl). Р.11 – 18.
  • 29. Greenberg Е. Р. The Group behavior of pseudomonas: Learning to fight bacterial biofilm infections in the Genomic Era. Oral report and slide presentation. In: 14 th North American cystic fibrosis conference. – November 9 – 12, 2000. – Baltimore, Maryland, USA. – Data on Highlights CD from the conference; www.cff.org.
  • 30. Hancock, R. E. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide О side chains/ R. E. Hancock, L. M. Mutharia, L. Chan et al //Infect. Immun. 1983. V. 42. Р.170 – 177.
  • 31. Hdiby, N. Prospects for the prevention and control of Pseudomonal infection in children with cystic fibrosis/ N. Hdiby //Pediatr. Drugs. 2000. V. 2 (6). Р. 451.
  • 32. Hoiby, N. Microbiology of lung infections in cystic fibrosis patients/ N. Hoiby// Acta Paediatr. Scand. Suppl. 1982. V. 301. Р. 33 – 54.
  • 33. Hunt, B. E. Macromolecular mechanisms of sputum inhibition of tobramycin activity / B. E Hunt, A. Weber, A. Berger // Antimicrob Agents Chemother. 1995. V. 39. Р. 34 – 39.
  • 34. Kahl, B. Persistent infection with small colony variant strains of Stafilococcus aureus in patients with cystic fibrosis / B. Kahl, M. Herrmann, A. S. Everding //J. Infect. Dis. 1998. V. 177 Р. 1023 – 9.
  • 35. Kobayashi, H. Clinical Management and therapy of airway biofilm disease/ H. Kobayashi //In: 11 th International Cogress on Inffectious Diseases. — Cancun, Mexico, march, 4 – 7, 2004. – Abstr. № 56.003. On disk.
  • 36. Kumon, H. A sandwich cup method for the penetration assay of antimicrobial agents through Pseudomonas exopolysaccharides/ H. Kumon, K. Tomochika, M. Ogawa, H. Ohmori // Microbiol. and Immunol. 1994. V.38. № 8. Р. 615 – 619.
  • 37. Labro, M.T. Anti¬inflammatory activity of macrolides: a new therapeutic potential? / M.T. Labro. J. Antimicrob. Chemother. 1998. V.41 (suppl. B). Р. 37 – 46.
  • 38. Le Conte, P. Lung distribution and pharmacokinetics of aerosolized tobramycin/ P. Le Conte, G, Potel, P. Peltier et al //Am Rev RespirDis. 1993. V. 147. Р. 1279 – 1282.
  • 39. Levy, J. Antibiotic activity in sputum / J. Levy //J. Pediatr 1986. V.108. Р. 841¬846.
  • 40. Liu, L. Ribosomal DNA¬directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients. L. Liu, T. Coenye, J. L. Burns et al //J. Clin. Microbiol. 2002. V.40. Р. 1210¬1213.
  • 41. Campbell, M. E. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis./M. E. Campbell, J. Foster, J. S. Lam et al //J. Clin. Microbiol. 1996. V. 34. Р. 1129¬1135.
  • 42. Moldawer, L. L. Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options / L. L. Moldawer, E. M. Copeland //Cancer. 1997. V. 79. Р. 1828-1839.
  • 43. Nguyen, T. Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease / Т. Nguyen, S. G. Louie, P. M. Beringer, M.A Gill //Curr. Opin. Pulm Med. 2002. V. 8. Р. 521¬528.
  • 44. Nixon, G. M.Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. G. M. Nixon, D. S. Armstrong, R. Carzino// J. Pediatr. 2001. V. 138. Р. 699¬704.
  • 45. Ojeniyi, B. Pseudomonas aeruginosa cross¬infection among patients with cystic fibrosis during a winter camp/ B. Ojeniyi, B. Frederiksen, N. Hoiby// Pediatr. Pulmonol. 2000. V. 29. Р.177¬181.
  • 46. Ojeniyi, B. Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients/ B. Ojeniyi, U. S. Petersen, N. Hoiby //APMIS. 1993. V. 101. Р. 168¬175.
  • 47. Percivai, S. L. MPhil biofilms and their potential in wound healing/S. L. Percivai, P. G. Bowler //Wounds. 2004. V. 16. №7. Р. 234¬240. 2004 Health management publications, http://www.medscape. com/viewarticle/484361.
  • 48. Podbielski, A. Cell density — dependent regulation: basic principles and effects on the virulence of Grampositive cocci / A. Podbielski, B. Kreikemeyer // Int. J. Infect. Dis. 2004. V. 8. Р. 81 — 95.
  • 49. Ramphal, R. The binding of antipseudomonal antibiotics to macromolecules from cystic fibrosis sputum / R. Ramphal, M. Lhermitte, M. Filliat, P. Roussel // J. Antimicrob Chemother. 1988. V. 22. Р. 483¬490.
  • 50. Ramsey, B.W. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl / B. W. Ramsey, M. S. Pepe, J. M. Quan et al// J. Med. 1999. V. 340. Р. 23¬30.
  • 51. Ratjen, F. Eradication of Pseudomonas aeruginosa with inhaled tobramycin in patients with cystic fibrosis/ F. Ratjen, G. Doring, W. Nikolaizik //Lancet. 2001. V. 358. Р. 983¬984.
  • 52. Romling, U. Achieving 100% typeability of Pseudomonas aeruginosa by pulsed¬field gel electrophoresis/ U. Romling, B. Tummler //J. Clin. Microbiol. 2000. V. 38. Р. 464¬465.
  • 53. Rosenfeld, M. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis / M. Rosenfeld, R. L. Gibson, S. McNamara et al //Pediatr. Pulmonol. 2001. V. 32. Р. 356¬366.
  • 54. Tenover, F. C. How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologists. Molecular Typing Working Group of the Society for Healthcare Epidemiology of America / F. C. Tenover, R. D. Arbeit, R. V. Goering //Infect. Control Hosp. Epidemiol. 1997. V. 18. Р. 426¬439.
  • 55. Wagner, Т. Effects of azithromycin on clinical isollates of Pseudomonas aeruginosa from cystic fibrosis patients/ Т. Wagner, G. Soong, S. Socol et al. //Chest. 2005. V.128. № 2. Р. 912¬919.
  • 56. Whitchurch, C. Extracellular DNA required for Bacterial Biofilm Formation/ C. Whitchurch, Т. Tolker-Nielsen, P. Ragas, J. Mattick //Science. 2002. V. 295. № 22. Р. 1487.
  • 57. Wiesemann, H. G. Placebo controlled, double blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in patients with cystic fibrosis / H. G. Wiesemann, G. Steinkamp, F. Ratjen et al //Pediatr. Pulmonol. 1998. V. 25. Р. 88¬92.
  • 58. Worlitzsch, D. Reduced oxygen concentrations in airway mucus contribute to the early and late pathogenesis of Pseudomonas aeruginosa cystic fibrosis airways infection/ D. Worlitzsch, R. Tarran, M. Ulrich et al / /J. Clin. Invest. 2002. V.109. Р.317¬325.